Cargando…

Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment

PURPOSE: Evaluation of patients’ ease of use of the redesigned, disposable, ready-to-use follitropin alfa pen during controlled ovarian stimulation for assisted reproductive technology. METHODS: This single-center, observational, open-label, single-arm study recruited infertile normo-ovulatory women...

Descripción completa

Detalles Bibliográficos
Autores principales:	Illingworth, Peter J, Lahoud, Robert, Quinn, Frank, Chidwick, Kendal, Wilkinson, Claire, Sacks, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051799/ https://www.ncbi.nlm.nih.gov/pubmed/24940048 http://dx.doi.org/10.2147/PPA.S58046

Ejemplares similares

Human factors engineering and design validation for the redesigned follitropin alfa pen injection device
por: Mahony, Mary C, et al.
Publicado: (2015)

A redesigned follitropin alfa pen injector for infertility: results of a market research study
por: Abbotts, Carole, et al.
Publicado: (2011)

Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction
por: Nawroth, Frank, et al.
Publicado: (2015)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
por: Bühler, Klaus
Publicado: (2015)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
por: Manzi, Lucio, et al.
Publicado: (2022)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
por: Patel, Nayana Hitesh, et al.
Publicado: (2023)

Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
por: Welcker, J Thomas, et al.
Publicado: (2010)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023)

In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta
por: Haakman, Olga, et al.
Publicado: (2020)

Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
por: Riccetti, Laura, et al.
Publicado: (2019)

Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
por: Agostinetto, Rita
Publicado: (2009)

Comparison of follitropin β administered by a pen device with follitropin β administered by a conventional syringe in patients undergoing IVF-ET
por: Kang, Hyuk-Jae, et al.
Publicado: (2011)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Ovulation induction with minimal dose of follitropin alfa: a case series study
por: Bruna-Catalán, Isidoro, et al.
Publicado: (2011)

The Effect of Follitropin Alfa in Controlled Ovarian Stimulation Protocol for In Vitro Fertilization Cycles
por: Prasetiawati, Novita, et al.
Publicado: (2023)

Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
por: Alper, Michael, et al.
Publicado: (2008)

A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
por: Gizzo, Salvatore, et al.
Publicado: (2016)

A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study
por: Bühler, Klaus, et al.
Publicado: (2011)

A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection
por: Esteves, Sandro C, et al.
Publicado: (2009)

Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting
por: Griesinger, Georg, et al.
Publicado: (2021)

A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration
por: Utsunomiya, Takafumi, et al.
Publicado: (2012)

A Novel Follitropin Analog Inhibits Follitropin Activity In Vitro
por: Azzam, Naiel, et al.
Publicado: (2021)

Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT
por: Hossein Rashidi, Batool, et al.
Publicado: (2021)

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2020)

A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
por: Bühler, Klaus, et al.
Publicado: (2014)

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2021)

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
por: Khoa, Le Dang, et al.
Publicado: (2020)

Psychometric Assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone
por: Pleil, Andreas M, et al.
Publicado: (2012)

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
por: Kaplan, Sigal, et al.
Publicado: (2021)

Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Chua, Su Jen, et al.
Publicado: (2021)

Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Venetis, Christos A., et al.
Publicado: (2023)

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency
por: Rinaldi, Leonardo, et al.
Publicado: (2016)

Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
por: Lee, Ji-Eun, et al.
Publicado: (2019)

Pen needle design influences ease of insertion, pain, and skin trauma in subjects with type 2 diabetes
por: Præstmark, Kezia A, et al.
Publicado: (2016)

Phase III trial comparing the efficacy and safety of recombinant‐ or urine‐derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo‐ovulation and undergoing ovulation induction with follitropin‐alfa
por: Ikenaga, Hideyuki, et al.
Publicado: (2016)

Highly purified human-derived follicle-stimulating hormone (Bravelle®) has equivalent efficacy to follitropin-beta (Follistim ®) in infertile women undergoing in vitro fertilization
por: Dickey, Richard P, et al.
Publicado: (2003)

Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study
por: Busingye, Doreen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o5oeprnctu2q6ht375u2guhk3f